Lannett launches generic Aggrenox
Lannett is offering aspirin and extended-release dipyridamole capsules in a dosage strength of 25 mg/200 mg.
The product, which is the generic of Boehringer Ingelheim’s Aggrenox capsules, 25 mg/200 mg, has a market value of approximately $158 million for the 12 months ended April 2019, according to IQVIA, although actual generic market values are expected to be lower.
"The launch of aspirin and extended-release dipyridamole capsules, an internally developed product, represents a meaningful opportunity,"Lannett CEO Tim Crew, said, adding "We continue to make progress on a number of operational fronts. Since January of this year, we have improved our capital structure with open market purchases of approximately $62 million of our term loans, which is in addition to the approximately $67 million of required annual loan amortization, added drug development expertise to our board of directors and, including aspirin and extended-release deipyridamole, launched seven new products."
The product, which is the generic of Boehringer Ingelheim’s Aggrenox capsules, 25 mg/200 mg, has a market value of approximately $158 million for the 12 months ended April 2019, according to IQVIA, although actual generic market values are expected to be lower.
"The launch of aspirin and extended-release dipyridamole capsules, an internally developed product, represents a meaningful opportunity,"Lannett CEO Tim Crew, said, adding "We continue to make progress on a number of operational fronts. Since January of this year, we have improved our capital structure with open market purchases of approximately $62 million of our term loans, which is in addition to the approximately $67 million of required annual loan amortization, added drug development expertise to our board of directors and, including aspirin and extended-release deipyridamole, launched seven new products."